Clinical Trial Summary Article

At a glance: CDK4/6 inhibitors in advanced breast cancer Cyclin-dependent kinase (CDK)4/6 inhibitors have become an important treatment option for patients with hormone receptor (HR)-positive advanced breast cancer (ABC). Here we outline the key efficacy and safety results reported thus far from the PALOMA, MONALEESA, and MONARCH series of clinical trials of palbociclib, ribociclib, and […]


Webcast Optimizing CDK 4/6 inhibition in HR+ HER2- advanced breast cancer Click on the presentation links (right) to view the individual free webcast sessions Click here to watch the full webcast Click on the presentation links below to watch the individual sessions by Javier Cortes, Nadia Harbeck and George W Sledge Jr. The webcast includes […]

Optimizing CDK4/6 inhibition in HR+ HER2- advanced breast cancer

Program launch date: 19th September 2020 Accreditation expiration date: 3rd December 2021 Welcome to this independent medical education program on the optimal use of CDK4/6 inhibitors to treat HR+ HER2- advanced breast cancer. This program is designed for global oncologists and other healthcare professionals involved in the diagnosis, treatment, and follow-up of patients with breast […]